Cargando…
Reversible Fulminant Hepatitis Secondary to Cocaine in the Setting of β-Blocker Use
Background. Fulminant hepatitis is acute hepatic injury with severe decline in hepatic function manifested by encephalopathy, hypercoagulable state, jaundice, renal failure, hypoglycemia, or a constellation of these symptoms in patients without preexisting liver disease. Etiologies include viral inf...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7243380/ https://www.ncbi.nlm.nih.gov/pubmed/32434395 http://dx.doi.org/10.1177/2324709620924203 |
_version_ | 1783537418942545920 |
---|---|
author | Sharma, Rohan Kapoor, Nidhi Chaudhari, Kaustubh Suresh Scofield, Robert Hal |
author_facet | Sharma, Rohan Kapoor, Nidhi Chaudhari, Kaustubh Suresh Scofield, Robert Hal |
author_sort | Sharma, Rohan |
collection | PubMed |
description | Background. Fulminant hepatitis is acute hepatic injury with severe decline in hepatic function manifested by encephalopathy, hypercoagulable state, jaundice, renal failure, hypoglycemia, or a constellation of these symptoms in patients without preexisting liver disease. Etiologies include viral infections, hepatotoxic drugs, autoimmune diseases, vaso-occlusive diseases, sepsis, and malignant infiltration. Case Report. A 56-year-old man presented with acute heart failure in the setting of cocaine use. The patient subsequently developed fulminant hepatic failure manifested by acute hypoglycemia, elevated liver enzyme, and worsening liver function, which resolved over 1 week with supportive care. The patient was on β-blocker, which was stopped during the admission. He was again admitted on several different occasion for cocaine-induced acute heart failure but did not develop hepatic failure as his β-blocker was discontinued. Discussion. Cocaine has been known to cause hepatotoxicity in humans. However, our patient developed fulminant hepatic failure in the setting of concomitant cocaine and β-blocker use likely secondary to unopposed α-adrenergic activity and ischemic hepatopathy. The patient did not develop hepatic failure on subsequent admissions with cocaine use after discontinuation of β-blockers. |
format | Online Article Text |
id | pubmed-7243380 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-72433802020-06-03 Reversible Fulminant Hepatitis Secondary to Cocaine in the Setting of β-Blocker Use Sharma, Rohan Kapoor, Nidhi Chaudhari, Kaustubh Suresh Scofield, Robert Hal J Investig Med High Impact Case Rep Case Report Background. Fulminant hepatitis is acute hepatic injury with severe decline in hepatic function manifested by encephalopathy, hypercoagulable state, jaundice, renal failure, hypoglycemia, or a constellation of these symptoms in patients without preexisting liver disease. Etiologies include viral infections, hepatotoxic drugs, autoimmune diseases, vaso-occlusive diseases, sepsis, and malignant infiltration. Case Report. A 56-year-old man presented with acute heart failure in the setting of cocaine use. The patient subsequently developed fulminant hepatic failure manifested by acute hypoglycemia, elevated liver enzyme, and worsening liver function, which resolved over 1 week with supportive care. The patient was on β-blocker, which was stopped during the admission. He was again admitted on several different occasion for cocaine-induced acute heart failure but did not develop hepatic failure as his β-blocker was discontinued. Discussion. Cocaine has been known to cause hepatotoxicity in humans. However, our patient developed fulminant hepatic failure in the setting of concomitant cocaine and β-blocker use likely secondary to unopposed α-adrenergic activity and ischemic hepatopathy. The patient did not develop hepatic failure on subsequent admissions with cocaine use after discontinuation of β-blockers. SAGE Publications 2020-05-21 /pmc/articles/PMC7243380/ /pubmed/32434395 http://dx.doi.org/10.1177/2324709620924203 Text en © 2020 American Federation for Medical Research https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Case Report Sharma, Rohan Kapoor, Nidhi Chaudhari, Kaustubh Suresh Scofield, Robert Hal Reversible Fulminant Hepatitis Secondary to Cocaine in the Setting of β-Blocker Use |
title | Reversible Fulminant Hepatitis Secondary to Cocaine in the Setting of β-Blocker Use |
title_full | Reversible Fulminant Hepatitis Secondary to Cocaine in the Setting of β-Blocker Use |
title_fullStr | Reversible Fulminant Hepatitis Secondary to Cocaine in the Setting of β-Blocker Use |
title_full_unstemmed | Reversible Fulminant Hepatitis Secondary to Cocaine in the Setting of β-Blocker Use |
title_short | Reversible Fulminant Hepatitis Secondary to Cocaine in the Setting of β-Blocker Use |
title_sort | reversible fulminant hepatitis secondary to cocaine in the setting of β-blocker use |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7243380/ https://www.ncbi.nlm.nih.gov/pubmed/32434395 http://dx.doi.org/10.1177/2324709620924203 |
work_keys_str_mv | AT sharmarohan reversiblefulminanthepatitissecondarytococaineinthesettingofbblockeruse AT kapoornidhi reversiblefulminanthepatitissecondarytococaineinthesettingofbblockeruse AT chaudharikaustubhsuresh reversiblefulminanthepatitissecondarytococaineinthesettingofbblockeruse AT scofieldroberthal reversiblefulminanthepatitissecondarytococaineinthesettingofbblockeruse |